NCT00390325 - Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2006

Primary Completion Date

January 30, 2017

Study Completion Date

December 22, 2022

Conditions

Hereditary Thyroid Gland Medullary CarcinomaLocally Advanced Thyroid Gland Medullary CarcinomaMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2BRecurrent Thyroid Gland Medullary CarcinomaSporadic Thyroid Gland Medullary CarcinomaStage III Thyroid Gland Medullary Carcinoma AJCC v7Stage IV Thyroid Gland Medullary Carcinoma AJCC v7Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

Interventions

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (3)

27710

Duke University Medical Center, Durham

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH